| Date | Title | | | 11/25/09 | Inspire Announces Webcast of Presentation at Piper Jaffray Health Care Conference| DURHAM, N.C.--(BUSINESS WIRE)--Nov. 25, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that
Christy L. Shaffer, Ph.D., President and CEO, and Thomas R. Staab, II,
CFO and Treasurer, will present at the 21st Annual Piper Jaffray Health
Care Conference on Wednesday, December 2, 2009 at 10:00 am ET in New
York City.
The webcast of the presentation will be available on Inspire's web site
at www.inspirepharm.com.
... |
|  | | 11/05/09 | Inspire Reports Third Quarter 2009 Financial Results|
Q3 2009 Revenue Increased by 26% over Q3 2008
Cash & Investments Balance Increased with Recent $115 Million Equity
Financing
DURHAM, N.C.--(BUSINESS WIRE)--Nov. 5, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today financial
results for the third quarter ended September 30, 2009, reporting a net
loss of $8.5 million or ($0.12) per common share.
Total revenue for the third quarter of 2009 was $... |
| | | 11/04/09 | Inspire Completes Patient Enrollment in Three Late-Stage Clinical Trials in Cystic Fibrosis, Dry Eye and Blepharitis| DURHAM, N.C.--(BUSINESS WIRE)--Nov. 4, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today patient
enrollment is complete in three of its late-stage clinical trials.
“We are pleased to be executing on our strategic plan with the
achievement of these patient enrollment milestones in the clinical
development programs for denufosol, PROLACRIA™ and AZASITE®,
as this places us in a position to have top-line results from all
... |
| | | 10/22/09 | Inspire Announces Date for Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results| DURHAM, N.C.--(BUSINESS WIRE)--Oct. 22, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that it
plans to report third quarter 2009 financial results on Thursday,
November 5, 2009 before the market opens. Inspire's President and CEO,
Christy L. Shaffer, Ph.D., and CFO and Treasurer, Thomas R. Staab, II,
will host a conference call and live webcast on Thursday, November 5,
2009 at 10:00 a.m. ET.
To access the confere... |
| | | 10/20/09 | Inspire's President and CEO Christy Shaffer Receives Cystic Fibrosis Foundation's Highest Award| DURHAM, N.C.--(BUSINESS WIRE)--Oct. 20, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that
Christy L. Shaffer, Ph.D., President and CEO, received the Breath of
Life Award, which is the most important recognition awarded to an
individual or company by the Cystic Fibrosis Foundation (CFF) for
extraordinary commitment and contributions to support the work of the
CFF. Dr. Shaffer was presented the award at the 23rd annual
Nor... |
| | | 10/15/09 | Inspire Announces Presentation at the North American Cystic Fibrosis Conference and Provides Enrollment Update for Phase 3 Cystic Fibrosis Trial|
- TIGER-2 Trial Enrollment Nearing Completion with 430 Patients
Enrolled -
DURHAM, N.C.--(BUSINESS WIRE)--Oct. 15, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today Inspire
scientists and collaborators will present data from the denufosol
tetrasodium cystic fibrosis (CF) program in a poster presentation at the
23rd Annual North American Cystic Fibrosis Conference (NACFC)
October 15 - 17, 2009 in Minneapolis, MN.
... |
| | | 09/09/09 | Inspire Committed to Helping Healthcare Providers and Patients During Erythromycin Ophthalmic Ointment Shortage| DURHAM, N.C.--(BUSINESS WIRE)--Sep. 9, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that it has
been communicating with the U.S. Food and Drug Administration (FDA) and
is increasing its production of AzaSite® (azithromycin
ophthalmic solution) 1% in response to the manufacturing supply shortage
of erythromycin ophthalmic ointment (0.5%). Erythromycin ophthalmic
ointment is a macrolide antibiotic routinely used in neonates for
... |
| | | 09/09/09 | Inspire Wins North Carolina Health & Life Sciences Award for Cystic Fibrosis Development Program| DURHAM, N.C.--(BUSINESS WIRE)--Sep. 9, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today it received
the North Carolina Health & Life Sciences Award in the category of
“Breakthrough Research” for its denufosol tetrasodium program for cystic
fibrosis (CF). This award recognizes innovative research that has the
potential to solve problems of great importance to science or society.
Inspire received the award at the annu... |
| | | 09/08/09 | Inspire Announces Webcasts of Presentations at Morgan Stanley, BioCentury and UBS Healthcare Conferences| DURHAM, N.C.--(BUSINESS WIRE)--Sep. 8, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Thomas
R. Staab, II, Chief Financial Officer and Treasurer, will present at the
Morgan Stanley Global Healthcare Unplugged Conference on Tuesday,
September 15, 2009 at 8:00 am ET, Christy L. Shaffer, Ph.D., President
and CEO, will present at the BioCentury Newsmakers Conference on
Wednesday, September 16, 2009 at 3:00 pm ET and Benjamin R. ... |
| | | 08/10/09 | Inspire Announces Closing of $115 Million Public Offering| DURHAM, N.C.--(BUSINESS WIRE)--Aug. 10, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the closing
of its previously announced public offering of 22,222,223 shares of its
common stock. The Company also announced that the underwriter exercised
in full its over-allotment option to purchase an additional 3,333,332
shares, bringing the total shares sold to 25,555,555 at a price of $4.50
per share for gross proceeds of $115 million. N... |
| | | 08/05/09 | Inspire Announces Pricing of $100 Million Common Stock Offering| DURHAM, N.C.--(BUSINESS WIRE)--Aug. 5, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today the pricing
of its previously announced public offering of its common stock at a
price to the public of $4.50 per share and an increase in the offering
size to 22.2 million shares. Inspire has granted Deutsche Bank
Securities Inc., the sole underwriter of the offering, an option to
purchase up to an additional 3.3 million shares of common stock t... |
| | | 08/04/09 | Inspire Announces Public Offering of Common Stock| DURHAM, N.C.--(BUSINESS WIRE)--Aug. 4, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today its
intention, subject to market and other conditions, to offer $80 million
of its common stock in a registered public offering pursuant to its
existing shelf registration statement. Inspire also intends to grant to
the underwriter of the offering an option to purchase additional shares
of common stock to cover over-allotments, if any. Inspire p... |
| | | 07/31/09 | Inspire Reports Second Quarter 2009 Financial Results| - 2009 Annual Financial Guidance Reaffirmed -
- CEO Succession Plan Announced -
DURHAM, N.C.--(BUSINESS WIRE)--Jul. 31, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today financial
results for the second quarter ended June 30, 2009, reporting a net loss
of $9.5 million or ($0.17) per share.
Total revenue for the second quarter of 2009 was $23.1 million, as
compared to $22.0 million for the second quarter of 2008, reflecting an
... |
| | | 07/28/09 | Inspire Announces Date for Conference Call and Webcast to Discuss Second Quarter 2009 Financial Results| DURHAM, N.C.--(BUSINESS WIRE)--Jul. 28, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that it
plans to report second quarter 2009 financial results on Friday, July
31, 2009 before the market opens. Inspire's President and CEO, Christy
L. Shaffer, Ph.D., and CFO and Treasurer, Thomas R. Staab, II, will host
a conference call and live webcast on Friday, July 31, 2009 at 10:00
a.m. ET.
To access the conference call,... |
| | | 07/21/09 | Inspire's Thomas Staab Named CFO of the Year by Triangle Business Journal| Company Also Receives Two Employee Wellness Awards
DURHAM, N.C.--(BUSINESS WIRE)--Jul. 21, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Thomas
R. Staab, II, Chief Financial Officer and Treasurer, was named CFO of
the Year in the Small Public Company category in Triangle Business
Journal’s 2009 CFO of the Year Award program. Awards were presented
to professionals in the Triangle area of North Carolina who exemplify
excelle... |
| | | 06/12/09 | Inspire Announces Presentations at European Cystic Fibrosis Society Annual Meeting| DURHAM, N.C.--(BUSINESS WIRE)--Jun. 12, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today Inspire
scientists and collaborators are presenting additional data from
TIGER-1, the Company’s first Phase 3 trial with denufosol tetrasodium
for the treatment of cystic fibrosis, at the European Cystic Fibrosis
Society annual meeting June 10 - 13, 2009 in Brest, France.
The oral poster presentation, “Effects of Denufosol ... |
| | | 06/04/09 | Inspire Announces Webcast of Presentation at Needham Life Sciences Conference| DURHAM, N.C.--(BUSINESS WIRE)--Jun. 4, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that
Christy L. Shaffer, Ph.D., President and CEO, will present at the 8th
Annual Needham Life Sciences Conference on Thursday, June 11, 2009 at
11:30 am ET in New York City.
The webcast of the presentation will be available on Inspire's web site
at www.inspirepharm.com.
An archived version of the webcast presentation will also ... |
| | | 05/15/09 | Inspire Announces Presentations at American Thoracic Society Annual Meeting| Data Presented from Phase 3 Cystic Fibrosis Trial with Denufosol Tetrasodium
DURHAM, N.C.--(BUSINESS WIRE)--May. 15, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today Inspire
scientists and collaborators will present data at the American Thoracic
Society (ATS) annual meeting May 15 - 20, 2009 in San Diego, CA.
The oral poster presentation, “Phase 3 Study of Denufosol Tetrasodium
for the Treatment of Cystic Fibrosis” (R.B. Moss, R.D... |
| | | 05/12/09 | Inspire Announces Webcast of Presentation at Deutsche Bank Health Care Conference| DURHAM, N.C., May 12, 2009 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Thomas
R. Staab, II, Chief Financial Officer and Treasurer, and Kim Brazzell,
Ph.D., Executive Vice President and Head, Ophthalmology Business, will
present at the Deutsche Bank 34th Annual Health Care Conference Tuesday,
May 19, 2009 at 8:10 am ET in Boston, MA.
The webcast of the presentation will be available on Inspire's web site
at www.insp... |
| | | 05/07/09 | Inspire Reports First Quarter 2009 Financial Results| DURHAM, N.C.--(BUSINESS WIRE)--May. 7, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today financial
results for the first quarter ended March 31, 2009, reporting a net loss
of $19.4 million or ($0.34) per share, which included a one-time,
non-recurring restructuring charge of $1.9 million, or ($0.03) per share.
Total revenue for the first quarter of 2009 was $14.3 million, as
compared to $9.7 million for the first quarter o... |
| | | 05/04/09 | Inspire Announces Poster Presentations at 2009 Association for Research in Vision and Ophthalmology Annual Meeting| DURHAM, N.C.--(BUSINESS WIRE)--May. 4, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the
presentation of data related to post-marketing open-label clinical and
nonclinical work with AzaSite® (azithromycin
ophthalmic solution) 1% in poster presentations at the 2009 Association
for Research in Vision and Ophthalmology (ARVO) annual meeting May 3-7,
2009 in Ft. Lauderdale, FL.
The following poster presentations will ... |
| | | 05/04/09 | Inspire Initiates Phase 2 Program with AzaSite(R) for the Treatment of Blepharitis| DURHAM, N.C.--(BUSINESS WIRE)--May. 4, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today it has
initiated a Phase 2 program with AzaSite® (azithromycin
ophthalmic solution) 1% to pursue a potential indication for the
treatment of blepharitis, an ocular disease characterized by
inflammation of the eyelids. AzaSite is currently approved by the
U.S. Food and Drug Administration (FDA) for the treatment of bacterial
conjunctivitis.... |
| | | 04/23/09 | Inspire Announces Date for Conference Call and Webcast to Discuss First Quarter 2009 Financial Results| DURHAM, N.C.--(BUSINESS WIRE)--Apr. 23, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that it
plans to report first quarter 2009 financial results on Thursday, May 7,
2009 before the market opens. Inspire's President and CEO, Christy L.
Shaffer, Ph.D., and CFO and Treasurer, Thomas R. Staab, II, will host a
conference call and live webcast on Thursday, May 7, 2009 at 10:00 a.m.
ET.
To access the conference call,... |
| | | 04/03/09 | Inspire Announces Presentations at 2009 American Society of Cataract and Refractive Surgery Annual Meeting| DURHAM, N.C., Apr 03, 2009 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that
Inspire scientists and collaborators are presenting information from the
Phase 4 program with AzaSite(R) (azithromycin
ophthalmic solution) 1% in two electronic poster presentations at the
2009 American Society of Cataract and Refractive Surgery (ASCRS) annual
meeting April 3 - 8, 2009 in San Francisco, CA.
The poster presentation titled, "Clini... |
| | | 03/10/09 | Inspire Announces Webcast of Presentation at Cowen Health Care Conference| DURHAM, N.C.--(BUSINESS WIRE)--Mar. 10, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that
Christy L. Shaffer, Ph.D., President and CEO, will present at the Cowen
and Company 29th Annual Health Care Conference Tuesday, March 17, 2009
at 11:00 am ET in Boston, MA.
The webcast of the presentation will be available on Inspire's web site
at www.inspirepharm.com.
An archived version of the webcast presentation will a... |
| | | 03/03/09 | Inspire Reports Fourth Quarter and Full Year 2008 Financial Results| DURHAM, N.C.--(BUSINESS WIRE)--Mar. 3, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today financial
results for the fourth quarter and year ended December 31, 2008,
reporting a net loss of $9.7 million or ($0.17) per common share for the
fourth quarter and a net loss of $51.6 million or ($0.91) per common
share for the full year.
Total revenue for the fourth quarter of 2008 was $18.9 million, as
compared to $13.9 mil... |
| | | 02/17/09 | Inspire Announces Date for Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results| DURHAM, N.C.--(BUSINESS WIRE)--Feb. 17, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that it
plans to report fourth quarter and full year 2008 financial results on
Tuesday, March 3, 2009 before the market opens. Inspire's President and
CEO, Christy L. Shaffer, Ph.D., and Executive Vice President and CFO,
Thomas R. Staab, II, will host a conference call and live webcast on
Tuesday, March 3, 2009 at 10:00 a.m. ET.
... |
| | | 02/10/09 | Inspire Elects Alan F. Holmer to Board of Directors| DURHAM, N.C.--(BUSINESS WIRE)--Feb. 10, 2009--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) today announced the
election of Alan F. Holmer to its Board of Directors, effective February
6, 2009.
Mr. Holmer was elected by the Board of Directors to fill a vacancy. He
will serve the remainder of a three-year term expiring at Inspire’s 2009
annual meeting of stockholders and is expected to be nominated for
re-election at the 2009 annual mee... |
| | | 02/03/09 | Inspire Announces Webcast of Presentation at BIO CEO Conference| DURHAM, N.C.--(BUSINESS WIRE)--
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that
Christy L. Shaffer, Ph.D., President and CEO, will present at the BIO
CEO & Investor Conference Tuesday, February 10, 2009 at 11:30 am ET in
New York City.
The webcast of the presentation will be available on Inspire's web site
at www.inspirepharm.com.
An archived version of the webcast presentation will also be available
thro... |
| | | 01/27/09 | Inspire Initiates Phase 3 Prolacria(TM) Dry Eye Trial under Special Protocol Assessment Agreement| DURHAM, N.C.--(BUSINESS WIRE)--Jan. 27, 2009--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today it has
reached agreement with the U.S. Food and Drug Administration (FDA)
through a Special Protocol Assessment (SPA) on the design of a Phase 3
clinical trial for Prolacria(TM) (diquafosol tetrasodium ophthalmic
solution) 2% for the treatment of dry eye disease and has recently
initiated enrollment in the trial.
Based on the SPA agreeme... |
| |
|
